Different serine and glycine metabolism in patients with schizophrenia receiving clozapine

Journal of Psychiatric Research

Volumn 46, Issue 6, 2012, Pages 811-818

  Hons, Jaromir ^a   Vasatova, Martina ^b   Cermakova, Eva ^c   Doubek, Pavel ^d   Libiger, Jan ^b  

^a REGIONAL HOSPITAL LIBEREC   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antipsychotics; Clozapine; Excitatory amino acids; Glycine; Schizophrenia; Serine

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASPARTIC ACID; CHLORPROMAZINE; CLOZAPINE; DEXTRO SERINE; EXCITATORY AMINO ACID; FLUPHENAZINE DECANOATE; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; HALOPERIDOL DECANOATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERINE; SERTINDOLE; ZIPRASIDONE;

ADULT; AMINO ACID ANALYSIS; AMINO ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

EID: 84861220884     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.03.015     Document Type: Article

References (66)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry 1989, (Suppl. 7):49-58.
2. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. Journal of Pharmacology and Experimental Therapeutics 1997, 283(1):226-234.
3. Baruah S., Waziri R., Hegwood T.S., Mallis L.M. Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry. Psychiatry Research 1991, 37:261-270.
4. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophrenia Research 2007, 90:41-51.
5. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry 2007, 164(10):1593-1602.
6. Carl G.F., Brogan M.P., Young B.K. Is plasma serine a marker for psychosis?. Biological Psychiatry 1992, 31:1130-1135.
7. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current Drug Targets-CNS & Neurological Disorders 2002, 1(2):183-189.
8. Evins A.E., Amico E.T., Shih V., Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of Neural Transmission 1997, 104:761-766.
9. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. American Journal of Psychiatry 2000, 157:826-828.
10. Evins A.E., Amico E., Posever T.A., Toker R., Goff D.C. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research 2002, 56(1-2):19-23.
11. Fuchs S.A., De Barse M.M., Scheepers F.E., Cahn W., Dorland L., de Sain-van der Velden M.G., et al. Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. European Neuropsychopharmacology 2008, 18(5):333-338.
12. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. A dose-finding trial of D-cycloserine added to neuroleptic for negative symptoms in schizophrenia. American Journal of Psychiatry 1995, 152:1213-1215.
13. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 1996, 153(12):1628-1630.
14. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D.S., Schoenfeld D.A., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 1999, 56(1):21-27.
15. Goff D.C., Freudenreich O., Evins A.E. Augmentation strategies in the treatment of schizophrenia. CNS Spectrums 2001, 6(11). 904, 907-911.
16. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 2003, 60:572-576.
17. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29:767-769.
18. Hatano T., Ohnuma T., Sakai Y., Shibata N., Maeshima H., Hanzawa R. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve - results from the Juntedo University Schizophrenia Projects (JUSP). Psychiatry Research 2010, 177:27-31.
19. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 1996, 169:610-617.
20. Heresco-Levy U., Javitt D.C., Ermilov M., Silipo G., Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology 1998, 1(2):131-135.
21. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 1999, 56(1):29-36.
22. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry 2002, 159(3):480-482.
23. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 2004, 55(2):165-171.
24. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 2005, 57(6):577-585.
25. Hons J., Zirko R., Ulrychova M., Cermakova E., Libiger J. D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects. Neuroendocrinology Letters 2008, 29(4):485-492.
26. Hons J., Zirko R., Ulrychova M., Cermakova E., Doubek P., Libiger J. Glycine serum level in schizophrenia: relation to negative symptoms. Psychiatry Research 2010, 176(2):103-108.
27. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 1994, 151:1234-1236.
28. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., et al. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2001, 4(4):385-391.
29. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
30. Konradsson A., Marcus M.M., Hertel P., Svensson T.H., Jardemark K.E. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 2006, 60(2):102-108.
31. Korpi E.R., Kaufmann C.A., Marnela K., Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Research 1987, 20:337-345.
32. Krystal J.H., Pery E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Archives of General Psychiatry 2005, 62:985-995.
33. Kutlan D., Presits P., Molnar-Perl I. Behavior and characteristics of amine derivatives obtained with o-phthaldialdehyde/3-mercaptopropionic acid and with o-phthaldialdehyde/N-acetyl-cysteine reagents. Journal of Chromatography A 2002, 949:235-248.
34. Kutlan D., Molnar-Perl I. New aspects of the simultaneous analysis of amino acids and amines as their o-phthaldialdehyde derivatives by high-performance liquid chromatography. Analysis of wine, beer and vinegar. Journal of Chromatography A 2003, 987:311-322.
35. Lane H., Chang Y., Liu Y., Chiu Ch, Tsai G. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia. Archives of General Psychiatry 2005, 62:1196-1204.
36. Leveque J.C., Macías W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. Journal of Neuroscience 2000, 20(11):4011-4020.
37. Lipina T., Labrie V., Weiner I., Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 2005, 179(1):54-67.
38. Lucca A., Cortinovis S., Lucini V. Serine and glycine metabolism in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1993, 17:947-953.
39. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Research 1990, 32:63-70.
40. Maeshima H., Ohnuma T., Sakai Y., Shibata N., Baba H., Ihara H., et al. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia - Juntedo University Schizophrenia Projects (JUSP). Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31(7):1410-1418.
41. Moghaddam B., Jackson M.E. Glutamatergic animal models of schizophrenia. Annals of the New York Academy of Sciences 2003, 1003:131-137.
42. Molnar-Perl I. Quantification of amino acids and amines in the same matrix by high-performance liquid chromatography, either simultaneously or separately. Journal of Chromatography A 2003, 987:291-309.
43. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. American Journal of Psychiatry 2005, 162:1738-1740.
44. Ohnuma T., Sakai Y., Maeshima H., Hatano T., Hanzawa R., Abe S., et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntedo University Schizophrenia Projects (JUSP). Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:1905-1912.
45. Ohnuma T., Arai H. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:29-39.
46. Olney J.W., Farber N.B. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. Journal of Clinical Psychiatry 1994, 55(9, Suppl. B):43-46.
47. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 1999, 33(6):523-533.
48. Perry T.L., Hansen S. Interconversion of serine and glycine is normal in psychotic patients. Psychiatry Research 1985, 15:109-113.
49. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry 1999, 156:145-147.
50. Schmitt A., Zink M., Müller B., May B., Herb A., Jatzko A., et al. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochemical Research 2003, 28(2):235-241.
51. Schwieler L., Engberg G., Erhardt S. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 2004, 52(2):114-122.
52. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. International Journal of Neuropsychopharmacology 2004, 7(1):1-8.
53. Sumiyoshi T., Jin D., Jayathilake K., Lee M., Meltzer H.Y. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. International Journal of Neuropsychopharmacology 2005, 8:451-455.
54. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001, 44:167-171.
55. Tsai G., Yang P., Chung L., Lange N., Coyle J.T. D-serine added to antipsychotics for treatment of schizophrenia. Biological Psychiatry 1998, 44(11):1081-1089.
56. Tsai G., Yang P., Chung L., Tsai I., Tsai Ch, Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry 1999, 156:1822-1825.
57. Tsai G.E., Lin P. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Current Pharmaceutical Design 2010, 16:522-537.
58. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2005, 72:225-234.
59. Vasanits A., Kutlan D., Sass P., Molnar-Perl I. Retention/quantification properties of the o-phthaldialdehyde-3-mercaptopropionic acid and the o-phthaldialdehyde-N-acetyl-L-cysteine amino acid derivatives in reversed-phase high-performance liquid chromatography. Journal of Chromatography A 2000, 870:271-287.
60. Waziri R., Wilcox J., Sherman A.D., Mott J. Serine metabolism and psychosis. Psychiatry Research 1984, 12(2):121-136.
61. Waziri R., Mott J. Drug effects on serine metabolism in psychiatric patients. Psychiatry Research 1986, 18:119-126.
62. Wilcox J., Waziri R., Sherman A.D., Mott J. Metabolism of an ingested serine load in psychotic and nonpsychotic subjects. Biological Psychiatry 1985, 20(1):41-49.
63. Williams J.B., Mallorga P.J., Conn P.J., Pettibone D.J., Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophrenia Research 2004, 71:103-112.
64. World Health Organization The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research 1993, World Health Organization, Geneva.
65. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biological Psychiatry 2005, 57:1493-1503.
66. Zhao M., Bada J.L. Determination of α-dialkylamino acids and their enantiomers in geological samples by high-performance liquid chromatography after derivatization with a chiral adduct of o-phthaldialdehyde. Journal of Chromatography A 1995, 690:55-63.